Haematological malignancies
Explore our latest news, features and educational resources in this specialist area.
Mogamulizumab recommended for previously treated mycosis fungoides and Sézary syndrome
Indirectly comparing mogamulizumab with evidence from people having standard care in the NHS suggests that people are likely to live longer with mogamulizumab., according to NICE final draft guidance.
Pembrolizumab recommended for Hodgkin lymphoma
NICE has issued draft guidance recommending pembrolizumab as an option for treating relapsed or refractory classical Hodgkin lymphoma.
#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin's Lymphoma
Quality Evidence Briefings, Blood and immune system conditions, Cancer, Oncology, Haematological malignancies, Oncology Room
#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin's Lymphoma
SMC accepts treatment for mantle cell lymphoma on an interim basis
Autologous anti-CD19-transduced CD3+ cells (KTE-X19) is accepted for use within NHS Scotland on an interim basis subject to ongoing evaluation and future reassessment.
NICE recommends treatment for early stage mycosis fungoides-type cutaneous T-cell lymphoma
Chlormethine gel is recommended in final draft guidance following the agreement of a new commercial discount.